Fig. 1From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United StatesFlow chart of irAE studies for seven FDA-approved ICIs: ICI toxicity burden causing tissue or organ disorders may exacerbate ICI-associated irAEsBack to article page